1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 2-12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione Compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof and a sub-maximal amount of a sulphonylurea(insulin secretagogue) to a mammal in need thereof. 2. A method according to claim 1 wherein the insulin secretagogue is glibenclamide glipizide gliclazide glimepiride tolazamide tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide or repaglinide. 3. A method according to any one of claim 1 or 2 which comprises the administration of 2 to 4 4 to 8 or 8 to 12 mg per day of Compound (I). 4. A method according to any one of claims 1 to 3 which comprises the administration of 2 to 4mg per day of Compound (I). 5. A method according to any one of claims 1 to 3 which comprises the method the administration of 4 to 8 mg per day of Compound (I). 6. A method according to any one of claims 1 to 3 which comprises the administration of 8 to 12 mg per day of Compound (I). 7. A method according to any one of claims 1 to 3 which comprises the administration of 2 mg per day of Compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof. 8. A method according to any one of claims 1 to 3 which comprises the administration of 4 mg per day of Compound (I). 9. A method according to any one of claims 1 to 3 which comprises the administration of 8 mg per day of Compound (I). 10. A pharmaceutical composition comprising of 2-12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy] benzyl]thiazolidine-24-dione Compound (I) ) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof and a sub-maximal amount of a sulphonylurea(insulin secretagogue) and a pharmaceutically acceptable carrier therefor. 11. A composition according to claim 14 or claim 15 wherein the insulin secretagogue is glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide or repaglinide.

暂无附图